A Phase 2 interventional study of Abiraterone Acetate and Prednisone in Prostate Cancer, sponsored by Cougar Biotechnology, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-15.
Sponsored by Cougar Biotechnology, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.
Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 41st largest by enrollment of the 69 interventional ones that give a count, is one of 5 that started in 2009, is one of 23 in phase 2, and was the 25th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Ontario Clinical Oncology Group (OCOG) · Sites in Canada
Ages 18+ · Men only
Emory University · Sites in United States
Ages 18+ · Men only
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Cancer Research Antwerp · Sites in Belgium
Ages 18+ · Men only
By country, each count listing its studies:
Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 26 · Phase 3 27 · Phase 4 9
First in 1994; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 77 across the 69 interventional studies. Of the 47 that completed or were terminated, 26 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 70 have an industry lead sponsor. The 10 most frequent:
This study is registered under Cougar Biotechnology, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Cougar Biotechnology, Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 37th largest by enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2009, is one of 20 in phase 2, and was the 18th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
7 of the studies testing leuprolide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05169112Phase 3Ottawa Hospital Research InstituteImpact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy | 2026-11 |
| NCT04302454Phase 3University Medical Center GroningenAndrogen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy | 2027-10-21 |
| NCT06627530Brazilian Clinical Research InstituteCOACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer | 2026-12 |
| NCT04249154McGill University Health Centre/Research Institute of the McGill University Health CentrePostop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer | 2026-12-15 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 70 studies testing leuprolide in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical research study is to find out how treatment with abiraterone acetate in combination with prednisone and a Luteinizing Hormone-Releasing Hormone (LHRH) analogue changes the tumor in comparison to treatment with an LHRH analogue alone.
Objectives:
Primary Objective:
To assess the difference in pathologic stage \< pT2 between Group A and Group B.
Secondary Objective:
Study Groups:
Participants who are eligible to take part in this study will be randomly assigned (as in the flip of a coin) to 1 of 2 groups:
Participants in both groups will receive the study drug(s) for about 3 months followed by a prostatectomy (prostate surgery) between 2 and 4 weeks after they stop taking the study drug(s).
Length of Study:
Participants will receive study drugs on this study for about 3 months before having surgery to remove their prostate about 2-4 weeks later. Participants will be removed from this study if the disease gets worse, if they experience intolerable side effects, or their study doctors feel that it is in their best interest to stop the study.
Long-Term Follow-Up:
Participants will return to the clinic 1 month, 3 months, 6 months, and then every 6 months (for up to 8 years) after your surgery for follow-up visits. Up to 66 patients will be take part in this study. All will be enrolled at M. D. Anderson after their surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) and 1,000 mg abiraterone acetate (AA) plus 5 mg of prednisone daily for 3 months prior to radical prostatectomy.
Drug: Abiraterone Acetate · Drug: Prednisone · Drug: LHRHa
Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) prior to radical prostatectomy.
Drug: LHRHa
1000 mg oral daily for 3 months followed by a prostatectomy.
Also known as: CB7630
5 mg orally daily.
LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.
Also known as: Lupron®, leuprolide, Zoladex®, goserelin
Number of Participants With a Pathology Tumor Stage of Less Than or Equal to Prostate Cancer Stage at Which the Tumor is Confined to the Prostate (pT2)
The table below shows number of participants in each treatment group with a pathology tumor stage less than or equal to pT2.
Time frame: At the end of Cycle 3 (at radical prostatectomy)
Number of Participants With a Positive Surgical Margin at Radical Prostatectomy
The table below shows number of participants in each treatment group who had positive surgical margins. A positive surgical margin is defined as tumor extending to the inked-surface or margin of the prostate.
Time frame: At the end of Cycle 3 (at radical prostatectomy)
Number of Participants With Prostate-Specific Antigen Response
The table below shows number of participants in each treatment group who achieved a prostate-specific antigen (PSA) response defined as a drop in PSA value to less than or equal to 0.2 ng/mL.
Time frame: Cycle 3 Day 1
The study was conducted from 20 November 2009 to 14 March 2013. Participants were recruited at 1 study center in the United States.
| Milestone | AA+LHRHa | LHRHa |
|---|---|---|
| Started | 44 | 22 |
| Received treatment | 44 | 21 |
| Completed | 44 | 21 |
| Not completed | 0 | 1 |
| Withdrew: Did not receive study treatment | 0 | 1 |
The table below shows number of participants in each treatment group with a pathology tumor stage less than or equal to pT2.
| participants | AA+LHRHa | LHRHa |
|---|---|---|
| Number of Participants With a Pathology Tumor Stage of Less Than or Equal to Prostate Cancer Stage at Which the Tumor is Confined to the Prostate (pT2) | 24 | 8 |
The table below shows number of participants in each treatment group who had positive surgical margins. A positive surgical margin is defined as tumor extending to the inked-surface or margin of the prostate.
| participants | AA+LHRHa | LHRHa |
|---|---|---|
| Number of Participants With a Positive Surgical Margin at Radical Prostatectomy | 6 | 6 |
The table below shows number of participants in each treatment group who achieved a prostate-specific antigen (PSA) response defined as a drop in PSA value to less than or equal to 0.2 ng/mL.
| participants | AA+LHRHa | LHRHa |
|---|---|---|
| Number of Participants With Prostate-Specific Antigen Response | 32 | 0 |
Collected over 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AA+LHRHa | — | 2/44 (4.5%) | 43/44 (97.7%) |
| LHRHa | — | 2/21 (9.5%) | 21/21 (100%) |
| Event | AA+LHRHa | LHRHa |
|---|---|---|
| Gastric IleusGastrointestinal disorders | 0/44 | 1/21 |
| Pelvic AbscessInfections and infestations | 0/44 | 1/21 |
| Infected LymphoceleInfections and infestations | 1/44 | 0/21 |
| Rib FractureInjury, poisoning and procedural complications | 1/44 | 0/21 |
| Bone PainMusculoskeletal and connective tissue disorders | 1/44 | 0/21 |
| Event | AA+LHRHa | LHRHa |
|---|---|---|
| Hot FlushVascular disorders | 37/44 | 18/21 |
| AnaemiaBlood and lymphatic system disorders | 23/44 | 8/21 |
| Alanine Aminotransferase IncreasedInvestigations | 22/44 | 7/21 |
| FatigueGeneral disorders | 19/44 | 10/21 |
| Aspartate Aminotransferase IncreasedInvestigations | 17/44 | 7/21 |
| InsomniaPsychiatric disorders | 3/44 | 6/21 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 9/44 | 5/21 |
| HypertensionVascular disorders | 10/44 | 3/21 |
| HyperglycaemiaMetabolism and nutrition disorders | 9/44 | 3/21 |
| HyperbilirubinaemiaHepatobiliary disorders | 8/44 | 1/21 |
| Age, Continuous(years) | AA+LHRHa | LHRHa | Total |
|---|---|---|---|
| Mean | 61.6 ± 7.14 | 59.9 ± 7.6 | 61 ± 7.29 |
| Sex: Female, Male(Participants) | AA+LHRHa | LHRHa | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 44 | 22 | 66 |
The record gives a start of Dec 2009, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide